Loading...
•
Mar 31, 2022
Cytek Biosciences Q1 2022 Earnings Report
Cytek Biosciences' first quarter revenue increased by 44% year-over-year, driven by continued demand across its diversified portfolio and expanded installed base.
Key Takeaways
Cytek Biosciences reported a strong start to 2022, with first-quarter revenue reaching $35.1 million, a 44% increase compared to the previous year. The company also expanded its installed base to 1,226 instruments and saw growth across its product and service offerings.
Total revenue for Q1 2022 was $35.1 million, a 44% increase year-over-year.
The installed base expanded to 1,226 instruments, with 116 instrument placements in Q1.
Service revenue more than doubled compared to the prior year.
The company expects full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.
Revenue by Segment
Forward Guidance
Cytek Biosciences expects full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...